We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Genetic Test Improves Ovarian Cancer Treatment

By LabMedica International staff writers
Posted on 12 Jan 2023

Ovarian cancer has the worst prognosis among all gynecological cancers due to delay in diagnosis as its symptoms are often minor and unclear. More...

Of late, the new PARP inhibitors as maintenance treatment for ovarian cancer after surgery and cytostatic therapy in newly-diagnosed ovarian cancer have demonstrated excellent results. However, the therapy can also cause serious side-effects, making it vital to target it to only those patients who stand to benefit the most from the treatment. Now, a new genetic test can identify ovarian cancer patients who can benefit from PARP inhibitors.

The genetic test developed at the University of Helsinki (Helsinki, Finland) and Helsinki University Hospital (Helsinki, Finland) using machine learning can identify patients whose tumors carry certain gene defects that are typical of ovarian cancer. The lesions are caused by a deficiency in the homologous recombination DNA repair pathway (HRD). These tumor types are the ones that are sensitive to PARP inhibitors. Their study has shown that each cancer type is associated with different characteristics of the genetic lesions related to HRD. In fact, it was important to develop a test optimized for ovarian cancer in order to advance the precision of therapies for the cancer type.

“The genetic test helps to identify patients who do not benefit from the drug, thus avoiding unnecessary treatment and the adverse effects associated with the drug,” said Specialist Anniina Färkkilä from HUS Helsinki University Hospital. “This therapy can now be administered to as many as half of the patients with ovarian cancer.”

“Clinical trials have shown that patients with HRD tumors have a strong response to PARP inhibitors, while the response of other patients is poor,” added Doctoral Researcher Fernando Perez Villatoro from the University of Helsinki. “The gene test and the algorithms are now freely available, and can be used in clinical care and trials to guide the treatment of ovarian cancer.”

Related Links:
University of Helsinki 
Helsinki University Hospital 


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Serological Pipet Controller
PIPETBOY GENIUS
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
New
Automated Biochemical Analyzer
iBC 900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.